After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

Q1 2025 Management View CEO Leonard Schleifer highlighted mixed performance in Q1 2025, with challenges in the retinal ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

The Company announced a 10-year agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to manufacture and supply Regeneron's commercial bulk drug product at Fujifilm's North Carolina campus. The ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

Regeneron Pharmaceuticals has a 52-week low of $525.99 and a 52-week high of $1,211.20. The firm has a market capitalization of $65.57 billion, a PE ratio of 15.67, a price-to-earnings-growth ...

Regeneron Pharmaceuticals has a one year low of $525.99 and a one year high of $1,211.20. The firm has a market cap of $65.88 billion, a PE ratio of 15.74, a price-to-earnings-growth ratio of 2.34 ...